Related Experiment Video
Updated: Jun 8, 2026
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
Glucagonoma syndrome.
B C Ravi Kumar1, C Balachandran, L Sabitha
1Department of skin and STD, Kasturba Medical College and Hospital Manipal-576119, India.
Indian Journal of Dermatology, Venereology and Leprology
|October 6, 2010
Summary
Glucagonoma syndrome, a rare condition involving pancreatic tumors, can present diversely. Early diagnosis is crucial for managing symptoms like necrolytic migratory erythema and diabetes mellitus.
Area of Science:
- Endocrinology
- Oncology
- Dermatology
Background:
- Glucagonoma is a rare neuroendocrine tumor originating from pancreatic alpha cells.
- It is characterized by a distinct clinical triad: necrolytic migratory erythema, weight loss, and diabetes mellitus.
- The syndrome's rarity and varied presentation can delay diagnosis.
Purpose of the Study:
- To report two cases of glucagonoma syndrome.
- To illustrate the diverse clinical manifestations of this rare condition.
- To emphasize the importance of timely diagnosis and management.
Main Methods:
- Case report analysis.
- Clinical presentation review.
- Diagnostic criteria assessment.
Main Results:
- Two patients presented with glucagonoma syndrome.
- Clinical features varied between the two cases, highlighting the syndrome's heterogeneity.
- Diagnostic delays were noted, underscoring challenges in recognition.
Conclusions:
- Glucagonoma syndrome requires a high index of suspicion due to its varied presentation.
- Early diagnostic efforts are essential for improved patient outcomes.
- Multidisciplinary management is often necessary for effective treatment.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.